medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Number 4

<< Back Next >>

Rev Invest Clin 2005; 57 (4)

On the tobacco use and tobacco poisoning in Mexico and Europe

de Micheli A, Izaguirre-Ávila R

Language: Spanish
References: 44
Page: 608-613
PDF size: 90.26 Kb.


ABSTRACT

The tobacco used for a long time by American and Caribbean natives was introduced into Europe at the end of XV century, and essentially during the XVI century, by travelers returning to their Fatherlands. After the tobacco industry was organized, several concerns arose regarding medical and social care for the workers in the tobacco factories. Medical and hygienic aspects were reflected in a whole chapter (the XVII) of the Ramazzini’s Treatise on Medicine of Work, published in 1700. Concerning social care for the workers’ families, the creation, April 1796, of nursery schools for the children of working women in tobacco factories of the New Spain must be recalled. In opposition to the predictions of some natives and visitors during the last centuries, with the passage of time, the tobacco habit instead of decreasing, became progressively more accentuated in all social classes. To aggravate conditions, at present, the noxious effects of the tobacco smoke are combined with those of environmental contamination. Recent epidemiological reports on the number and health conditions of smokers, as well as the National Antitobacco Program in Mexico, are mentioned.


REFERENCES

  1. Benzoni G. La Storia del Mondo Nuovo. Venecia. Tip. de Francesco Rampazzetto, 1565.

  2. Novo S. Notas para la historia del tabaco. Artes de México, año XV. No. 119, p 71.

  3. Monardes N. Historia medicinal de las cosas que se traen de nuestras Indias occidentales. Sevilla. Impr. de Alonso Escribano, 1574.

  4. Clusius C. Exoticorum libri decem. Amberes. Tip. Plantiniana de Rafalengio, 1605.

  5. Navarro J. Jardín americano (Intr. X. Lozoya). México. UNAM, IMSS, ISSSTE, 1992, pp. 137-138 (F. 212).

  6. Laín Entralgo P. Historia de la medicina. Barcelona: Salvat Editores, S. A.; 1978, p. 356.

  7. Hernández F. Historia natural de la nueva España. México: UNAM; 1959, Vol 1, p. 80.

  8. Ramazzini B. De morbis artificum diatriba. Módena, 1700

  9. Ravicio D. Compendiaria descrittione della virtú, e facoltá del tabacco. Venecia: Tip. de Evangelista Deuchino; 1628.

  10. de Sahagún B. Historia general de las cosas de Nueva España. México: Ed. Porrúa, S. A. (Col. “Sepan Cuantos”, No 300); 1999.

  11. de Ajofrín F. Diario del viaje a la Nueva España. (Sel., Intr., Notas de H. Moreno García). México, SEP, 1986, pp. 66-7.

  12. Calderón de la Barca F. La vida en México. Carta XLIII. México: Ed. Porrúa, S. A.; 2003, p. 349.

  13. Lombardo de Ruiz S. La ciudadela. México: UNAM; 1980.

  14. AGNM. Real Hacienda. Ramo Tabaco. Tomo 482.

  15. AGNM. Real Hacienda. Ramo Tabaco. Tomo 172.

  16. Vila-San Juan JL. La vida y la época de Amadeo I. Barcelona: Ed. Planeta, S. A.; 1997, p. 138.

  17. Calderón de la Barca F. Op. Cit. Carta VIII, p. 60.

  18. Calderón de la Barca F. Op. Cit. Carta XI, p. 92.

  19. Clavijero FX. Historia antigua de México. México: Ed Porrúa, S. A.; 1945, T II, L VII, Cap. LXIX.

  20. Cornelio Tácito C. Historias. L I. C XXII, 2 (Trad. J. Tapia Zúñiga). México: UNAM; 1995, p. 13.

  21. SSA. El consumo de tabaco en México y Encuesta Nacional de Adicciones. México. SSA, 2000.

  22. Lazcano-Ponce EC, Hernández-Ávila M. La epidemia de tabaquismo. Epidemiología, factores de riesgo y medidas de prevención. Salud Pública Mex 2002; 44(Supl. 1): S1-S2.

  23. Fernández E, Schiaffino A, Borrás JM. Epidemiología del tabaquismo en Europa. Salud Pública Mex 2002; 44(Supl. 1): S11-S19.

  24. Kuri-Morales F, Alegre Díaz J, Mata-Miranda Ma. del Pilar, Hernández-Ávila M. Mortalidad atribuible al consumo de tabaco en México. Salud Pública Mex 2002; 44(Supl. 1): S29-S33.

  25. Salazar-Martínez E, Sánchez-Zamorano LM, López-Padilla LA, Estrada-Nájera A, Lazcano-Ponce EC, Hernández-Ávila M. El tabaquismo y su fracción atribuible a la enfermedad isquémica cardiaca. Salud Pública Mex 2002; 44(Supl. 1): S34-S41.

  26. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease. J Am Coll Cardiol 2004; 43: 1731-7.

  27. Blann AD, McCollum CN. Adverse influence of cigarette smoking on the endotelium. Thromb Haemost 1993; 70: 707-11.

  28. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke. En The Edimburg Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.

  29. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost 1998; 79: 549-53.

  30. Manila MN, Silveira A, Hawe W, Eriksson P, Aillaud MF, Juhan I, et al. The HIFMECH Study Group: Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of beta-fibrinogen genotype and environmental factors. The HIFMECH Study. Thromb Haemost 2004; 92: 1240-9.

  31. Sinha S, Luben RN, Welch A, Bingham S, Wareham NJ, Day NE, Khaw KT. Fibrinogen and cigarette smoking in men and women in the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population. Eur J Cardiovasc Prev Rehabil 2005; 12: 144-50.

  32. Fusegawa Y, Handa S. Platelet aggregation induced by ADP or epinephrine is enhanced in habitual smokers. Thromb Res 2000; 97: 287-95.

  33. Nowak J, Murray JJ, Oates JA, Fitzgeralds GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987; 76: 6-14.

  34. Selley ML, Bartlett MR, McGuiness JA, Ardlie NG. Effects of acrolein on human platelet aggregation. Chem Biol Interact 1990; 76: 101-9.

  35. Davis J, Sheldon L, Watanabe I, Arnold J. Passive smoking affects endothelium and platelets. Arch Intern Med 1989; 149: 386-9.

  36. Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis 2003; 46: 31-8.

  37. Rodríguez J, Benavides F, Villaverde C, Pena E, Flor F, Trave P. Randomised clinical trial of an intensive intervention into life-styles of patients with hyperfibrinogenaemia in primary prevention of cardiovascular pathology in primary health care. Aten Primaria 2005; 35: 260-4.

  38. Morita H, Ikeda H, Haramaki N, Eguchi H, Imaizumi T. Only two-week smoking cessation improves platelet aggregability and intraplatelet redox imbalance of long-term smokers. J Am Coll Cardiol 2005; 45: 589-94.

  39. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 2004; 45(Suppl. 2): S3-S9.

  40. Taylor R, Cumming R, Woodward A, et al. Passive smoking and lung cancer: A cumulative meta-analysis. Aust N Z J Public Health 2001; 25: 203-11.

  41. Vázquez-Segovia LA, Sesma-Vázquez S, Hernández-Ávila M. El consumo de tabaco en los hogares de México: resultado de la Encuesta de Ingresos y Gastos de los Hogares, 1984-2000. Salud Pública Mex 2002; 44(Supl. 1): S76-S81.

  42. Kaplan GA, Lynch JW. Socioeconomic considerations in the primordial prevention of cardiovascular disease. Prev Med 1999; 29: S30-S35.

  43. Chávez Domínguez RC, López Antuñano FJ, Regalado Pineda J, Espinoza Martínez M. Consumo de tabaco, una enfermedad social. Rev Inst Nal Enf Resp Mex 2004; 17(3): 204-14.

  44. Informe de la Organización Panamericana de la Salud, 1992.




2020     |     www.medigraphic.com